Mazapertine
Mazapertine is an antipsychotic medication that belongs to the class of atypical antipsychotics. It is primarily used in the treatment of schizophrenia and other psychotic disorders. Mazapertine is known for its unique pharmacological profile, which includes a combination of dopamine and serotonin receptor antagonism.
Pharmacology[edit | edit source]
Mazapertine acts on multiple neurotransmitter systems in the brain. It primarily functions as an antagonist at the dopamine D2 receptors and serotonin 5-HT2A receptors. This dual action is believed to contribute to its efficacy in reducing both positive and negative symptoms of schizophrenia.
Mechanism of Action[edit | edit source]
The mechanism of action of Mazapertine involves blocking the dopamine D2 receptors, which helps in reducing the overactivity of dopamine that is often associated with psychotic symptoms. Additionally, its antagonistic effect on serotonin 5-HT2A receptors helps in modulating mood and cognitive functions, which can be beneficial in treating the negative symptoms of schizophrenia.
Indications[edit | edit source]
Mazapertine is indicated for the treatment of:
- Schizophrenia
- Bipolar disorder (off-label use)
- Other psychotic disorders
Side Effects[edit | edit source]
Common side effects of Mazapertine include:
Less common but more serious side effects may include:
Dosage and Administration[edit | edit source]
Mazapertine is typically administered orally. The dosage varies depending on the severity of the condition being treated and the patient's response to the medication. It is important to follow the prescribing physician's guidelines and adjust the dosage as necessary.
Contraindications[edit | edit source]
Mazapertine is contraindicated in patients with:
- Known hypersensitivity to Mazapertine or any of its components
- Severe liver disease
- Severe kidney disease
Interactions[edit | edit source]
Mazapertine may interact with other medications, including:
- Other antipsychotics
- Antidepressants
- Antihypertensive drugs
- CYP3A4 inhibitors
Research and Development[edit | edit source]
Mazapertine is still under investigation for its full range of therapeutic effects and potential new indications. Ongoing research aims to better understand its long-term efficacy and safety profile.
See Also[edit | edit source]
References[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD